
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ayrton Announces UK MHRA Approval of Next Gen Nicotine Inhaler for Smoking Cessation
Details : MHRA approved first and only nicotine inhaler enabling rapid absorption via the lungs to help smokers replace, cut down, and ultimately quit smoking.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
